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Novel Mechanisms and Targets
Miscellaneous Agents
Karen L. Reckamp, MD
Increased understanding of the molecular biology of lungcancer has led to substantial progress in the treatment of
lung cancer and stimulated further research toward finding
novel therapeutics. This session covered drugs that exploit
well-known pathways through unique mechanisms, including
an antifolate, an anthracycline/topoisomerase II inhibitor, a
peroxisome proliferator-activated receptor- (PPAR-) ago-
nist, and aromatase and estrogen inhibitors. Others explored
innovative targets, including an integrin inhibitor, a telomer-
ase antagonist, an antiapoptotic agent, a mitotic inhibitor, a
vascular disrupting agent, and a Janus-associated kinase
(JAK) 2 inhibitor.
Pralatrexate
Pralatrexate is an antifolate that inhibits dihydrofolate
reductase which leads to the blockade of DNA synthesis and
ultimately tumor cell death. Phase I investigations suggested
antitumor activity, and mucositis was the most common
adverse event.1 Pralatrexate was evaluated in a randomized
phase II trial (PDX-012) compared with erlotinib efficacy as
second-line therapy for non-small cell lung cancer (NSCLC).
The 1-year overall survival rate was 28% for pralatrexate
versus 18% for erlotinib, whereas the median survival was
6.7 months for pralatrexate and 7 months for erlotinib. Pro-
gression-free survival was similar for the two treatment
groups with a hazard ratio (HR) of 0.91. Mucositis was the
most frequent adverse event (AE), which led to treatment
discontinuation and 14% experienced a treatment-related se-
rious AE (SAE) including three deaths. In a preplanned
subset analysis investigating efficacy by tumor histology, a
benefit was demonstrated in patients with nonsquamous his-
tology.
Amrubicin
In extensive disease small cell lung carcinoma (ED-
SCLC), complete response to therapy occurs in less than 20%
and median survival is 8 to 10 months, and hence, new
therapies are needed. Amrubicin is a synthetic 9-amino-
anthracycline and topoisomerase II inhibitor. Its primary
toxicity is myelosuppression but it has not been shown to
have significant cardiotoxicity. Amrubicin has been studied
as first- and second-line therapy for ED-SCLC with promis-
ing results in both chemotherapy sensitive and refractory
disease. Results from EORTC 08062 evaluated amrubicin as
a single agent or in combination with cisplatin versus etopo-
side/cisplatin as first-line treatment for patients with ED-
SCLC.2 Response rates were highest in the amrubicin/cispla-
tin arm of this three-arm trial, amrubicin alone 61%,
amrubicin/cisplatin 77%, and etoposide/cisplatin 63%. He-
matologic toxicity was similar in all arms, and primary
prophylaxis with pegfilgrastim was added to the regimens. A
large, randomized, second-line trial (ACT-1) is ongoing in
patients with refractory disease ED-SCLC, N  620.
Efatutazone (CS-7017)
PPARs are transcription factors belonging to the li-
gand-activated nuclear hormone receptor superfamily and
contribute to adipogenesis, lipid and glucose metabolism, and
cellular function; and efatutazone (CS-7017) is a PPAR-
agonist. Dysregulation of PPAR activity is associated with
obesity, diabetes, cardiovascular disease, and cancer. PPAR
has been shown to be expressed in multiple malignancies,
including lung cancer, and its activation can inhibit angio-
genesis, reduce inflammation, and block tumor-stromal inter-
actions. Efatutazone has demonstrated a synergistic effect in
an in vivo NSCLC model when combined with carboplatin,
and in a phase I trial evaluating monotherapy in advanced
solid tumors, the drug was well-tolerated with dose-limiting
toxicities related to fluid retention. Adiponectin was elevated
post-treatment at each dose level and may serve as a useful
biomarker for efatutazone. A phase II, front-line trial, the
combination of efatutazone with carboplatin and paclitaxel,
has recently completed enrollment and a second-line study
with erlotinib is actively enrolling patients.
Volociximab
Volociximab is an IgG4 chimeric monoclonal antibody
that inhibits fibrinectin binding to 51 integrin.3 Integrins
belong to a superfamily of transmembrane glycoprotein re-
ceptors involved in the regulatory process of embryogenesis,
inflammation, bone metabolism, apoptosis, cell proliferation,
angiogenesis, and tumor metastasis. A phase I trial of vo-
lociximab in solid tumors showed mild toxicities without
dose-limiting toxicity and a single infusion reaction without
partial responses. A phase IB study of volociximab in com-
bination with carboplatin and paclitaxel in advanced NSCLC
confirmed that the combined therapy was well tolerated and
demonstrated six patients with partial response and an addi-
tional 12 with stable disease of 18 evaluable patients.
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Antiestrogens
The Women’s Health Initiative trial examined post-
menopausal estrogen and progestin compared with placebo
and found increased lung cancer mortality by the use com-
bined hormone therapy.4 Both estrogen receptor  and aro-
matase are commonly expressed in lung cancers and elevated
levels predict for a poor prognosis.5 In a murine lung model,
the combination of anastrozole and fulvestrant reduced tumor
formation by 90%, and the tumors that developed demon-
strated a significantly lower proliferative index. Based on this
data, a randomized trial evaluating anastrozole and fulves-
trant with bevacizumab versus bevacizumab as maintenance
therapy has been initiated for advanced NSCLC after first-
line therapy.
Imetelstat
Telomerase activity is found in approximately 90% of
human cancer and has been implicated in the proliferative
potential of tumors and the maintenance of tumor stem cells.
A human telomerase antagonist, imetelstat, produced reduced
colony formation and inhibition of metastatic disease in both
in vitro and in vivo lung cancer models.6 Phase I studies have
demonstrated that the drug is well tolerated. An ongoing
phase II trial is exploring imetelstat as maintenance therapy
after platinum-based induction therapy with or without bev-
acizumab for patients with advanced NSCLC. Patients are
randomized 2:1 to imetelstat given on days 1 and 8 of a
21-day cycle versus standard of care with a primary end point
of progression-free survival.
Custirsen (OGX-011)
Clusterin is an antiapoptotic protein that is cytoprotec-
tive that can be induced by various standard anticancer
therapies, which results in resistance. Clusterin inhibits en-
doplasmic reticulum vacuolization and protein aggregation
under stress conditions and interacts with and inhibits acti-
vated Bax. It is an ubiquitin-binding protein that enhances
COMMD1 and Ik-B degradation, thereby enhancing NF-kB
transcriptional activity. Custirsen (OGX-011) is a second-
generation phosphorothioate MOE gapmer, which increases
resistance to enzymatic degradation and increases drug half-
life.7 Custirsen has been investigated in a phase II study in
combination with gemcitabine and platinum as first-line ther-
apy for NSCLC and demonstrated a 14-month overall sur-
vival in 81 patients evaluated. Serum clusterin is under
evaluation as a predictive biomarker for survival in ongoing
trials. A phase III front-line trial in advanced NSCLC is
planned.
Litronesib
Litronesib is an Eg5 mitotic kinase 1 inhibitor, which
promotes monopolar mitotic spindle formation, and has dem-
onstrated antitumor activity in multiple in vivo models, in-
cluding NSCLC and SCLC. In a phase I trial, the inhibition
of mitotic activity was demonstrated in skin biopsies and
tumor tissue after litronesib treatment. An adaptive multitu-
mor phase II trial is planned and a study in SCLC as
maintenance treatment after first-line therapy is ongoing.
Bavituximab
Bavituximab is a phosphatidylserine-targeting mono-
clonal antibody with vascular-disrupting and immune-modu-
lating properties. Phosphatidylserine provides a tumor-spe-
cific target for bavituximab, and through antibody-dependent
cell-mediated cytotoxicity, the drug causes blood vessel oc-
clusion and destruction and exhibits synergy with chemother-
apy.8 A phase I monotherapy trial has been completed with
eight patients who experienced stable disease but without
objective responses. SAEs included grade 3 hypertension
and pulmonary embolus. Bavituximab is being investi-
gated in ongoing phase II trials in NSCLC as first-line
therapy with carboplatin and paclitaxel and second-line
therapy with docetaxel.
AZD1480
Signal transducer and activator of transcription 3
(STAT3) is a point of convergence for multiple oncogenic
signaling pathways. Constitutive activation of STAT3 within
tumor cells and stromal cells promotes cancer cell prolifera-
tion, invasion, angiogenesis, and immune evasion. STAT3
plays important role in both tumor cells and the tumor
microenvironment to facilitate the progression of cancer.
JAK2 is important in activating STAT3 and promoting on-
cogenesis. JAK2 is a target in myeloproliferative and hema-
tologic malignancies, and recent investigations have been
initiated in solid tumors. AZD1480 is a pyrazol-3-yl pyrimi-
din-4-amines and a potent Jak2 inhibitor. AZD1480 inhibits
cell proliferation in Jak2 V617F mutant tumors found in
myeloproliferative diseases. AZD1480 has also been shown
to suppress the growth of human xenograft tumors harboring
constitutive Stat3 activity.9 Ongoing trials with AZD1480
include a phase I monotherapy study and combination ther-
apy with docetaxel.
Future Directions
These therapeutics in development represent only a
fraction of new molecules under exploration. Knowledge of
mechanisms of lung cancer growth and invasion is rapidly
improving, leading to better therapies and identification of
potential biomarkers to cultivate personalized therapy with
the goal of improving outcomes for lung cancer patients.
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